Oncology Acute Care Follow-up Intervention Study
This study is looking at a new way to help cancer patients better use Oncology Acute Care (OAC) services at Parkland Health. If you have cancer, are getting chemotherapy, and recently visited the emergency department (ED) within 30 days of treatment, you might be eligible. The study will test if sending structured messages through MyChart and text messages, called "Follow-up messaging," can help you know when to use OAC instead of the ED. Researchers will track how long it takes for you to have another cancer treatment-related ED visit over a maximum of two years. The goal is to see if these messages can reduce ED visits by increasing your awareness and use of OAC services.
- Study design
- This is a pragmatic randomized controlled crossover study with a planned enrollment of 200 participants. You would be randomly assigned to either receive usual care or the follow-up messages.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- You would be followed for up to two years to see how long it takes until your next cancer treatment-related ED visit.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Oncology Acute Care Follow-up Intervention Study
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Arthur Hong, MD, MPH · PRINCIPAL_INVESTIGATOR · University of Texas Southwestern Medical Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Time to the next cancer treatment related ED visit.2 years maximum
Evaluate whether structured MyChart + text messaging after hospital/ED discharge decreases time to the next cancer treatment-related ED visit compared with usual care.